RFA
SUPN icon

Reilly Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Reilly Financial Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,000
Closed -$31K – 964
2016
Q1 		$31K Buy
+2,000
New +$26.1K 0.01% 480

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Reilly Financial Advisors's SUPN Position: Q3 2019 in Review

Reilly Financial Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 1,500 shares — an estimated $50K sold.

Reilly Financial Advisors first reported a position in SUPN in Q2 2016 and held it in 13 quarters. The position peaked at $90K in Q2 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

  • Reilly Financial Advisors reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Reilly Financial Advisors sold 1,500 Supernus Pharmaceuticals shares in Q3 2019, an estimated $50K.
  • Reilly Financial Advisors first reported a position in Supernus Pharmaceuticals in Q2 2016 and held it in 13 quarters.
  • Reilly Financial Advisors's Supernus Pharmaceuticals position peaked at $90K in Q2 2018.
  • 243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Reilly Financial Advisors's 13F filing for Q3 2019, filed 15 Oct 2019.